Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients
|
|
- Barnard Willis
- 5 years ago
- Views:
Transcription
1 Nephrol Dial Transplant (2003) 18 [Suppl 3]: iii42 iii46 DOI: /ndt/gfg1011 Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients Kazuhiro Shiizaki 1, Shigeo Negi 1, Masahide Mizobuchi 1, Ikuji Hatamura 2, Nobuhiko Narukawa 1, Toshifumi Sakaguchi 1, Yukiko Kitabata 1, Shinji Sumikado 1 and Tadao Akizawa 1 1 Center of Blood Purification Therapy and 2 The First Department of Pathology, Wakayama Medical University, Wakayama, Japan Abstract Background. The impetus to develop percutaneous calcitriol injection therapy (PCIT) was the lack of therapeutic tools to treat secondary hyperparathyroidism (2HPT) resistant to medical therapy. Methods. Nine dialysis patients resistant to intravenous calcitriol or calcitriol analogues underwent daily PCIT 5 10 times consecutively. The PCIT involved the injection of a volume of calcitriol equal to that of the enlarged parathyroid glands (PTGs) under ultrasonographic guidance. All patients had follow-up intravenous calcitriol after PCIT. Results. The serum intact PTH concentration was markedly reduced following PCIT and was maintained for 12 weeks with intravenous calcitriol without significant changes in serum adjusted calcium and phosphorus concentrations. All patients tolerated PCIT without serious adverse events. Serum bone alkaline phosphatase concentrations and the volume of the enlarged PTGs were also significantly reduced. Conclusion. PCIT is a safe and effective treatment, which may also suppress parathyroid hyperplasia and improve bone turnover for refractory 2HPT. Keywords: calcitriol; end-stage renal disease (ESRD); interventional ultrasonography; renal osteodystrophy; secondary hyperparathyroidism parathyroidectomy autotransplantation (PTx AT) is still necessary to control severe 2HPT resistant to medical therapy. General anaesthesia is necessary for PTx AT, which can be dangerous for high-risk patients with pulmonary or cardiovascular disorders, especially as repeated operations may be needed in cases of recurrent or persistent hyperparathyroidism. The development of ultrasonography has made it possible to perform percutaneous ethanol injection therapy (PEIT) in patients with refractory 2HPT, and this is now known to be as effective as PTx AT [5]. However, there are some adverse side effects, such as laryngeal palsy, the difficulty of PTx AT following failed PEIT and the necessity for specialists in all these techniques and procedures. Calcitriol (1,25-dihydroxy vitamin D 3 ), which is the most active metabolite of vitamin D, controls parathyroid gland (PTG) growth and suppresses the synthesis and secretion of parathyroid hormone (PTH) [6,7]. It has been reported that intravenous administration of calcitriol suppresses PTH dose dependently [3] but, for the many patients with advanced 2HPT that is resistant to intravenous calcitriol, effective and safe therapeutic tools, such as direct injection of calcitriol into the PTG (PCIT), are developed. In the present study, the effects of PCIT on serum concentrations of PTH, Ca, P and bone markers, and on the volume of the PTG were investigated. Introduction New agents for the control of secondary hyperparathyroidism (2HPT), including calcium (Ca)-free phosphorus (P) binders, active vitamin D derivatives and calcimimetics, have been developed recently [1 4]. However, Correspondence and offprint requests to: Kazuhiro Shiizaki, Center of Blood Purification Therapy, Wakayama Medical University, Kimiidera Wakayama , Japan. shiizaki@wakayama-med.ac.jp Subjects and methods Case studies Nine patients undergoing regular haemodialysis for endstage renal disease (ESRD) participated in the present study (Table 1). All patients had severe 2HPT resistant to more than 3 months of intravenous administration of vitamin D derivatives. The study was approved by the local medical ethics committee, and informed consent was obtained from each patient. # 2003 European Renal Association European Dialysis and Transplant Association
2 PCIT for 2HPT of uraemia Table 1. Background characteristics of the patients Demographic data No. of patients 9 (7 male, 2 female) Underlying renal disease CGN 5, nephrosclerosis 1, unknown 3 Age 59.1"6.72 (51 75) years Duration of dialysis 16.3"7.43 (2 27) years Baseline data Serum i-pth 716"311 pguml Serum adjusted Ca 10.8"0.61 mgudl Serum phosphorus 6.11"1.76 mgudl Serum BAP 161"74.5 IUul Serum i-bgp 178"108 nguml No. of enlarged PTGs 5.11"1.54 glands Total volume of PTGs 1.67"0.95 cm 3 Z-score by DXA 1.11"0.68 Data are means"sd. CGN, chromic glomerulonephritis; BAP, bone alkaline phosphatase; i-bgp, intact bone Gla protein; DXA, dual energy X-ray absorptiometry. Percutaneous calcitriol injection therapy (PCIT) The enlarged PTGs were examined by ultrasonography (SSD 5500, Aloka, Tokyo, Japan) and their sizes were estimated by 3D measurement (pu63 a3 b 3c) [8]. Calcitriol injection was performed using the same type of needle as used for PEIT (KM-N type, Hakko, Tokyo, Japan) [5]. Under ultrasonographic guidance, the needle was inserted into the centre of the PTG. If the volume of the PTG was )0.5 cm 3, we made several insertions in different sites of the PTG in order to saturate it with calcitriol solution. The PCIT was performed once a day for 5 10 consecutive days (6.56"1.51) (mean"sd). The injected volume of calcitriol solution (1 mguml) was estimated to be same as the volume of each gland (mean dose of calcitriol: 2.33"1.00 mg per one injection, 15.7"8.29 mg per total injections). There was good correlation between dosage and the total volume of the PTG (r 2 s0.838, P-0.01) (Figure 1). In patients with multiple enlarged PTGs, all detectably enlarged glands were treated by PCIT at the same time, even if they existed bilaterally. After PCIT, all patients were treated with intravenous calcitriol at the end of every haemodialysis session. The initial dose, 1 mg per session, was altered according to the serum Ca and intact PTH (i-pth) concentrations, which were measured periodically (dose of calcitriol 4 and 12 weeks after PCIT: 0.86"0.48 and 0.86"0.63 mg per haemodialysis session, respectively). Laboratory measurements and radiological examinations Concentrations of serum i-pth, adjusted Ca (calculated by Payne formula) [9], P, bone alkaline phosphatase (BALP) and intact bone Gla protein (i-bgp) were obtained for all patients before and after the series of PCIT. In seven of the patients, these data were also obtained 12 weeks after PCIT. Serum i-pth concentration was measured by the twoantibody method using Allegro 1 i-pth (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). Serum BALP and i-bgp levels were measured by precipitation with wheat germ lectin using an Iso-ALP test kit (Roche Diagnostics GmdH, Mannheim, Germany) and by immunoradiometric assay using a BGP-IRMA kit (Yuka-Medias, Tokyo, Japan), respectively. Concentrations of serum Ca, P and albumin were determined with an automated analyser (TBA-200FR, Toshiba, Tokyo, Japan). Total PTG volumes were calculated using ultrasonography before and, in seven patients, at 12 weeks after PCIT. Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA) (DPX-L, GE Lunar, Madison, WI, USA). Technetium-99m methoxyisobutylisonitrile imaging ( 99m Tc-MIBI) or thallium- 201-technetium-99 m subtraction scintigraphy (Tl-Tc) of the PTG was carried out for all patients in order to rule out the existence of ectopic PTG. Statistical analysis Data were expressed as mean"sd. Data were analysed by simple correlation or Student s t-test, and a P value was considered statistically significant. Results iii43 Patient characteristics Table 1 shows relevant laboratory data of the patients before PCIT. The mean serum i-pth concentration was 716"311 pguml, indicating severe 2HPT in spite of intravenous vitamin D therapy. The mean adjusted Ca and P concentrations were 10.8"0.61 and 6.11" 1.76 mgudl, respectively, so these patients were diagnosed as refractory 2HPT resistant to medical treatment. In addition, the high concentrations of bone metabolic markers (mean serum BAP and i-bgp levels were 161"74.5 IUul and 178"108 nguml, respectively) and low bone mineral content by DXA (mean Z-score: 1.11"0.68) suggested bone mineral loss because of high turnover bone disease resulting from the 2HPT. Ectopic PTG was not detected by 99m TC-MIBI or Tl-Tc in any of the patients. Fig. 1. Relationship between injected calcitriol dose and total PTG volume before PCIT (ns9) (injected calcitriol dosestotal PTG volumeq0.733, r 2 s0. 838, P-0.01). Changes in the laboratory data after PCIT The PCIT series significantly reduced serum i-pth concentrations (177"112 pguml: P-0.01); the mean reduction rate was 74.3"14.0%. In contrast, serum adjusted Ca and P concentrations did not change significantly throughout the study period (adjusted Ca
3 iii44 K. Shiizaki et al. Fig. 2. Changes in serum i-pth, adjusted calcium (Ca) and phosphorus (P) concentrations before and after PCIT (ns9). After PCIT, serum i-pth concentrations were significantly reduced, but serum adjusted Ca and P concentrations did not change significantly. (*P-0.01 vs before PCIT). and P concentrations after PCIT were 11.6"1.06 and 5.84"1.11 mgudl, respectively) (Figure 2). Increased concentrations of serum BALP and i-bgp did not change significantly as a result of PCIT (BALP and i-bgp concentrations after PCIT: 177"78.5 IUul and 248"210 nguml, respectively). Serum i-pth concentration 12 weeks after PCIT Twelve weeks after PCIT, serum i-pth concentrations in seven patients showed a significant reduction compared with values before PCIT (761"340 vs 474" 223 pguml: P-0.05) (Figure 3); however, serum adjusted Ca and P concentrations did not change significantly (10.8"0.67 vs 10.6"0.88 mgudl and 6.14"1.88 vs 5.69"1.12 mgudl, respectively). Effects of PCIT on bone metabolic markers In seven patients, bone markers tended to decrease as a result of PCIT and subsequent intravenous calcitriol treatment. The reduction in serum BALP concentration was significant 12 weeks after PCIT (176"78.2 vs 127"67.0 IUul; P-0.05) (Figure 4). Effect of PCIT on PTG volume Total PTG volumes were significantly reduced 12 weeks after PCIT compared with volumes before PCIT (1.78"0.96 vs 1.31"1.20 cm 3 ; P-0.05) (Figure 5). Discussion Secondary hyperparathyroidism from chronic renal failure causes many complications, including uraemic Fig. 3. Change in serum i-pth concentration 12 weeks after PCIT (ns7). The serum i-pth concentrations were significantly decreased 12 weeks after PCIT (P-0.05 vs before PCIT). bone disease [10,11], which are detrimental to quality of life and prognosis; therefore, control of 2HPT is essential for such patients. In Japan, intravenous calcitriol and 22-oxacalcitriol are used to suppress parathyroid function in patients with mild or moderate 2HPT [2]. However, some patients with 2HPT become resistant to these conventional therapies because of their poor effect on PTH reduction anduor complications of hypercalcaemia, so PCIT was developed to treat severe 2HPT resistant to medical therapies. Kitaoka et al. reported the efficacy and safety of direct injection of calcitriol into the PTG three times a week for 2 weeks [12]. However, the follow-up period
4 PCIT for 2HPT of uraemia iii45 Fig. 4. Changes in serum bone alkaline phosphatase (BALP) and intact bone Gla protein (i-bgp) concentrations before and 12 weeks after PCIT (ns7). Serum BALP concentrations were significantly decreased 12 weeks after PCIT (P-0.05 vs before PCIT). Fig. 5. Changes in total PTG volume before and 12 weeks after PCIT (ns7). Total PTG volume was significantly decreased by PCIT and the follow-up calcitriol intravenous therapy (*P-0.05 vs before PCIT). of their study was only 6 weeks and the changes in bone markers caused by PCIT were not investigated. In the present study, injection times for each patient were adjusted to suppress PTH concentrations sufficiently, so the mean serum i-pth concentrations after PCIT were reduced to 177"112 pguml (the mean reduction rate was 74.3"14.0%). In contrast, serum adjusted Ca and P concentrations did not change significantly during the treatment with PCIT. Moreover, serum i-pth concentrations 12 weeks after PCIT were significantly reduced compared with before PCIT, without significant changes in serum Ca and P. These results suggest that 2HPT was significantly suppressed by PCIT, and the response of the PTG cells to intravenous calcitriol therapy had recovered. This suppression of 2HPT might improve the high turnover bone disease caused by 2HPT as evidenced by a significant reduction in serum BALP concentrations. We also confirmed a significant reduction of PTG volume 12 weeks after PCIT, which is another finding supporting its ability to suppress 2HPT. Fukagawa et al. reported a significant decrease in PTG volume after 12 weeks of oral calcitriol pulse therapy and hypothesized that the apoptosis was induced in PTG cells by the high concentration of calcitriol [8]. The in vivo induction of apoptosis in parathyroid cells by percutaneous maxacalcitol injection therapy (PMIT) has also been reported [13]. The regression of enlarged PTG after PCIT is presumed to result from the decreased number of parathyroid cells by apoptosis; however, the precise mechanism for this process remains under investigation. It was reported that the level of vitamin D receptors (VDRs) in PTG was significantly reduced in advanced nodular hyperplasia, and this is considered to be the pathogenesis of the PTG resistance to vitamin D therapy [14]. Bolus oral or intravenous calcitriol administration is reported to improve resistance to calcitriol by up-regulation of the VDR in PTG cells [15 17]. Thus, up-regulation of VDR by PCIT may be another mechanism of the suppression of 2HPT. In summary, we clarified that PCIT and subsequent intravenous calcitriol administrations suppress 2HPT, high turnover bone disease and PTG hyperplasia without remarkable adverse events, including hypercalcaemia.
5 iii46 PCIT is another therapeutic option for severe 2HPT and an alternative to PEIT or PTx AT. Acknowledgements. The authors thank Dr Masafumi Kitaoka (Division of Endocrinology and Metabolism, Showa General Hospital, Tokyo, Japan) for training in parathyroid intervention techniques under ultrasonography. References 1. Slatopolsky EA, Burke SK, Dillon MA et al. RenaGel 1, a nonabsorbed calcium- and aluminium-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999; 55: Akizawa T, Suzuki M, Akiba T et al. Long-term effect of 1,25- dihydroxy-22-oxavitamin D 3 on secondary hyperparathyroidism in hemodialysis patients: one-year administration study. Nephrol Dial Transplant 2002; Koshikawa S, Akizawa T, Kurokawa K et al. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. Nephron 2002; 90: Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: Kitaoka M, Fukagawa M, Ogata E, Kurokawa K. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int 1994; 46: Cozzolino M, Lu Y, Finch J et al. p21 WAF1 and TGF-a mediate parathyroid growth arrested by vitamin D and high calcium. Kidney Int 2001; 60: Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The K. Shiizaki et al. effects of calcium, phosphate and vitamin D. J Clin Invest 1995; 96: Fukagawa M, Okazaki R, Takano K et al. Regression of parathyroid hypertrophy by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 1990; 323: Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973; 15: Rao DS, Shin MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993; 328: Ganesh S, Stack A, Levin N et al. Association of elevated serum PO 4,Ca3PO 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: Kitaoka M, Fukagawa M, Fukuda N et al. Direct calcitriol injections into enlarged parathyroid glands in chronic dialysis patients with severe parathyroid hyperfunction. Nephrology 1995; 1: Shiizaki K, Hatamura I, Negi S et al. Clinical effects and changes of parathyroid cells induced by percutaneous maxacalcitol injection therapy (PMIT) in patients with secondary hyperparathyroidism (2HPT). J Am Soc Nephrol 2002; 13: 194A 14. Fukuda N, Tanaka H, Tominaga Y et al. Decreased 1,25- dihydroxyvitamin D 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: Levine S, Song M. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 1996; 7: Patel R, Ke Q, Hsu H. Regulation of calcitriol receptor and mrna in normal and renal failure rats. Kidney Int 1994; 45:
Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia
Kidney International, Vol. 64 (2003), pp. 992 1003 Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia KAZUHIRO SHIIZAKI, 1 IKUJI HATAMURA,
More informationCase Report Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy
SAGE-Hindawi Access to Research International Nephrology Volume 211, Article ID 246734, 6 pages doi:1.461/211/246734 Case Report Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism
More informationDifferent effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism
Nephrol Dial Transplant (996) : 8-87 Original Article Nephrology Dialysis Transplantation Different effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe
More informationBasic and clinical aspects of parathyroid hyperplasia in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease M Fukagawa 1, S Nakanishi 1 and JJ Kazama
More informationKobe University Repository : Kernel
Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms
More informationGlycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy
Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationMedical and surgical aspects of parathyroidectomy
Kidney International, Vol. 56, Suppl. 73 (1999), pp. S-65 S-69 Medical and surgical aspects of parathyroidectomy MASAFUMI FUKAGAWA, YOSHIHIRO TOMINAGA, MASAFUMI KITAOKA, TAKATOSHI KAKUTA, and KIYOSHI KUROKAWA
More informationUltrasound examination in diagnosis of morphological variants of parathyroid hyperplasia in patients with secondary hyperparathyroidism
Ultrasound examination in diagnosis of morphological variants of parathyroid hyperplasia in patients with secondary hyperparathyroidism Poster No.: C-0304 Congress: ECR 2015 Type: Authors: Keywords: DOI:
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationHypercalcaemia is associated with poor mental health in haemodialysis patients: results from Japan DOPPS
Nephrol Dial Transplant (2007) 22: 1658 1664 doi:10.1093/ndt/gfm008 Advance Access publication 13 February 2007 Original Article Hypercalcaemia is associated with poor mental health in haemodialysis patients:
More informationA calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication
Kidney International, Vol. 53 (1998), pp. 223 227 A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication JOHN E. ANTONSEN, DONALD
More informationInfluence of parathyroid mass on the regulation of PTH secretion
http://www.kidney-international.org & 26 International Society of Nephrology Influence of parathyroid mass on the regulation of PTH secretion E Lewin 1,2 and K Olgaard 2 1 Nephrological Department B, The
More informationSecondary hyperparathyroidism an Update on Pathophysiology and Treatment
Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Klaus Olgaard Copenhagen Budapest Nephrology School August 2007 HPT IN CRF Renal mass Ca 2+ 1,25(OH) 2 D 3 CaR Hyperparathyroidism
More informationPathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention
NDT Plus (2008) 1 [Suppl 3]: iii2 iii8 doi: 10.1093/ndtplus/sfn079 Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention Shunsuke
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationReduction of functioning parathyroid cell mass by ethanol
Kidney International, VoL 46 (1994), PP. 1110 1117 Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients MASAFUMI K1TAOKA, MASAFUMI FUKAGAWA,1 IETSURO OGATA,
More informationRenal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young
Chapter 6 Renal Osteodystrophy Eric W. Young I. Introduction Renal osteodystrophy refers to bone disease that occurs in patients with kidney disease. Bone disease occurs across the full spectrum of kidney
More informationThe relationship between parathyroid enlargement and parathyroid hormone levels in patients undergoing hemodialysis; EMR(Electronic Medical Record)
Volume 118 No. 19 2018, 545-561 ISSN: 1311-8080 (printed version); ISSN: 1314-3395 (on-line version) url: http://www.ijpam.eu ijpam.eu The relationship between parathyroid enlargement and parathyroid hormone
More informationTechnetium-99m Sestamibi Scintigraphy Pattern in Patients with Secondary Hyperparathyroidism
. 2009 May;2(2):16-20 Original Article AJNT Technetium- Sestamibi Scintigraphy Pattern in Patients with Secondary Hyperparathyroidism Ahmed A Kandeel a*, Mohamed A Hawary b and Hisham S Ebaid c a Oncology
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationThe role of calcimimetics in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,
More informationGuidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism
Nephrol Dial Transplant (16) 11 [Suppl 3]: 6-101 Nephrology Dialysis Transplantation Guidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism E. Fernandez 1 and F.
More informationYueming Sun Æ Huihua Cai Æ Jianfeng Bai Æ Hanlin Zhao Æ Yi Miao
World J Surg (2009) 33:1674 1679 DOI 10.1007/s00268-009-0086-3 Endoscopic Total Parathyroidectomy and Partial Parathyroid Tissue Autotransplantation for Patients with Secondary Hyperparathyroidism: A New
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More information... . : ... PTH.
IRMA Email msarookhani@qumsacir * CRD GFR D [1,25OH 2 D 3 ] SHPT GFR» «KDOQI SHPT Ca * P P P Selectra Overt HPT = = Ca * P P > GM II DSL i IRMA ± ± ± Ca * P % % % % % % % % % % % % % % % % pgml = = > ±
More informationAbnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism
Nephrol Dial Transplant (1996) 11: 1292-1298 Original Article Mephrology Dialysis Transplantation Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism. Berdud, A.
More informationMarie-Claude Monier-Faugere, Hanna Mawad, and Hartmut H. Malluche
Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal- Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease Marie-Claude
More informationHigh-intensity focussed ultrasound (HIFU) treatment in uraemic secondary hyperparathyroidism
Nephrol Dial Transplant (2012) 27: 76 80 doi: 10.1093/ndt/gfr590 Advance Access publication 19 October 2011 High-intensity focussed ultrasound (HIFU) treatment in uraemic secondary hyperparathyroidism
More informationSURGERY FOR RENAL HYPERPARATHYROIDISM - EXPERIENCE OF 640 CASES -
Nagoya J. Med. Sci. 60. 15-22, 1997 INVITED REVIEW ARTICLE SURGERY FOR RENAL HYPERPARATHYROIDISM - EXPERIENCE OF 640 CASES - HIROSHI TAKAGI,* YOSHIHIRO TOMINAGA,** Yun TANAKA,* and KAZUHARU UCHIDA** 'Department
More informationBsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients
Clinical Chemistry / BSMI POLYMORPHISM OF THE VITAMIN D RECEPTOR GENE Bsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients Jacopo Tagliabue, MD,1 Marco
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationTitle:Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Author's response to reviews Title:Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism Authors: Li Fang (fangli@njmu.edu.cn)
More informationComparison between Whole and Intact Parathyroid Hormone Assays
tap_926 42..49 Therapeutic Apheresis and Dialysis 15(Supplement 1):42 49 doi: 10.1111/j.1744-9987.2011.00926.x Therapeutic Apheresis and Dialysis 2011 International Society for Apheresis Comparison between
More informationTotal Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism
The Journal of International Medical Research 2011; 39: 978 987 Total Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism J NARANDA 1,2, R EKART
More informationhypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause
hyperparathyroidism A 68-year-old woman with documented osteoporosis has blood tests showing elevated serum calcium and parathyroid hormone (PTH) levels: 11.2 mg/dl (8.8 10.1 mg/dl) and 88 pg/ml (10-60),
More informationCalcium x phosphate product
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL
More informationCell Biology of Parathyroid Gland Hyperplasia in Chronic Renal Failure
REVIEW J Am Soc Nephrol 11: 1141 1152, 2000 Cell Biology of Parathyroid Gland Hyperplasia in Chronic Renal Failure TILMAN B. DRÜEKE Institut National de la Santé et de la Recherche Médicale U507 and Division
More informationPhosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer
Hemodialysis International 2015; 19:5459 Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer Toru SANAI, 1
More informationCalcimimetic Compound Upregulates Decreased Calcium- Sensing Receptor Expression Level in Parathyroid Glands of Rats with Chronic Renal Insufficiency
J Am Soc Nephrol 15: 2579 2587, 2004 Calcimimetic Compound Upregulates Decreased Calcium- Sensing Receptor Expression Level in Parathyroid Glands of Rats with Chronic Renal Insufficiency MASAHIDE MIZOBUCHI,*
More informationInternational Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: Vol.7, No.4, pp ,
International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: 0974-4304 Vol.7, No.4, pp 560-565, 2014-2015 Comparison of Calcium, Phosphate and Intact Parathyroid Hormone Levels Pre- and Post-Parathyroidectomy
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationOriginal Article. Introduction. serum calcium and phosphorus levels in Japanese patients, having a longer average dialysis vintage.
Nephrol Dial Transplant (2008) 23: 328 335 doi:10.1093/ndt/gfm534 Advance Access publication 23 August 2007 Original Article Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable
More informationTotal parathyroidectomy with autotransplantation in patients with renal hyperparathyroidism: indications and surgical approach
270 HORMONES S. Gourgiotis 2006, 5(4):270-275 ET AL Research paper Total parathyroidectomy with autotransplantation in patients with renal hyperparathyroidism: indications and surgical approach Stavros
More informationUltrasound in clinical setting of secondary hyperparathyroidism
REVIEW JN EPHROL 00( 0000; 00) : 000-000 DOI: 10.5301/jn.5000219 Ultrasound in clinical setting of secondary hyperparathyroidism Mario Meola 1,2, Ilaria Petrucci 1,2, Adamasco Cupisti 2 1 S. Anna School
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationLong-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism
Nephrol Dial Transplant (2009) 24: 982 989 doi: 10.1093/ndt/gfn654 Original Article Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism
More informationAmol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through
Research Article ISSN: 0974-6943 Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through www.jpronline.info Comparison of efficacy and safety of Cinacalcet versus Calcitriol
More informationNew vitamin D analogs
Kidney International, Vol. 63, Supplement 85 (2003), pp. S83 S87 New vitamin D analogs EDUARDO SLATOPOLSKY, JANE FINCH, and ALEX BROWN Renal Division, Department of Internal Medicine, Washington University
More informationEfficacy of intraoperative parathyroid hormone monitoring to predict success of parathyroidectomy for secondary hyperparathyroidism
J Korean Surg Soc 2012;83:1-6 http://dx.doi.org/10.4174/jkss.2012.83.1.1 ORIGINAL ARTICLE JKSS Journal of the Korean Surgical Society pissn 2233-7903 ㆍ eissn 2093-0488 Efficacy of intraoperative parathyroid
More informationSensipar (cinacalcet)
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationTransient Thyrotoxicosis After Parathyroidectomy in a Hemodialysis Patient with Secondary Hyperparathyroidism
Case Report Transient Thyrotoxicosis After Parathyroidectomy in a Hemodialysis Patient with Secondary Hyperparathyroidism Chieko Hamada, Yuichi Tanaka, Tomoko Sakamoto, Kayo Kaneko, Ichiyu Shou, Mitsumine
More informationTitle:Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Author's response to reviews Title:Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism Authors: Li Fang (fangli@njmu.edu.cn)
More informationMarcin Barczynski, 1 Aleksander Konturek, 2 Alicja Hubalewska-Dydejczyk, 2. Filip Gołkowski, 1 Stanislaw Cichon, 1 Piotr Richter, 1 Wojciech Nowak
3 rd Chair and Department of General Surgery 1 and Chair and Department of Endocrinology 2 Jagiellonian University, Medical College Head: Prof. Wojciech Nowak, MD, PhD INTRAOPERATIVE BILATERAL INTERNAL
More informationBone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases
Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationPathogenesis of secondary hyperparathyroidism
The International Journal of Artificial Organs / Vol. 32 / no. 2, 2009 / pp. 75-80 Review Pathogenesis of secondary hyperparathyroidism MARIO COZZOLINO, SABINA PASHO, GIUDITTA FALLABRINO, LAURA OLIVI,
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationNew biological targets for CKD- MBD: From the KDOQI to the
New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationNuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)
Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism
More informationConsiderations for the Treatment of Secondary Hyperparathyroidism in Renal Failure
DISEASEOF THE MONTH Considerations for the Treatment of Secondary Hyperparathyroidism in Renal Failure ARNOLD J. FELSENFELD Department of Medicine, West Los Angeles Veterans Affairs Medical Center, and
More informationRenal osteodystrophy with special emphasis on secondary hyperparathyroidism
RENAL OSTEODYSTROPHY WITH SPECIAL EMPHASIS ON SECONDARY HYPERPARATHYROIDISM Artigo Original Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 9-18 Renal osteodystrophy with special emphasis on secondary hyperparathyroidism
More informationRace Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients
J Am Soc Nephrol 11: 330 334, 2000 Race Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients AJAY GUPTA,* LEE R. KALLENBACH, GERARD ZASUWA,* and GEORGE W. DIVINE *Division of Nephrology
More informationRisk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism
Ho et al. BMC Nephrology (2017) 18:12 DOI 10.1186/s12882-016-0421-5 RESEARCH ARTICLE Open Access Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients
More informationKey words: Vitamin D analogues, alfacalcidol, calcitriol, secondary hyperparathyroidism, renal dialysis
Oral cal ORAL CALCITRIOL VERSUS ORAL ALFACALCIDOL FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS RECEIVING HEMODIALYSIS: A RANDOMIZED, CROSSOVER TR IAL Samantha Moe 1, Lori D Wazny 2, Janet
More informationComplications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease
Med Clin N Am 89 (2005) 549 561 Complications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease Shona Pendse, MD, Ajay K. Singh, MB, MRCP(UK)* Renal Division, Brigham and
More informationCinacalcet suppresses calcification of the aorta and heart in uremic rats
original article http://www.kidney-international.org & 28 International Society of Nephrology see commentary on page 1229 Cinacalcet suppresses calcification of the aorta and heart in uremic rats Takehisa
More informationResearch Article Prognostic Importance of Fibroblast Growth Factor-23 in Dialysis Patients
International Nephrology, Article ID 602034, 6 pages http://dx.doi.org/10.1155/2014/602034 Research Article Prognostic Importance of Fibroblast Growth Factor-23 in Dialysis Patients Nilgül Akalin, 1 YJldJz
More informationSecondary hyperparathyroidism (SHPT) is a common
Cinacalcet Effectively Reduces Parathyroid Hormone Secretion and Gland Volume Regardless of Pretreatment Gland Size in Patients with Secondary Hyperparathyroidism Hirotaka Komaba,* Shohei Nakanishi, Akira
More informationPRIMARY HYPERPARATHYROIDISM
PRIMARY HYPERPARATHYROIDISM HYPERPARATHYROIDISM Inappropriate excess secretion of Parathyroid Hormone in Primary Hyperparathyroidism Appropriate Hypersecretion in Secondary Hyperparathyroidism PTH and
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationHormonalandMineralChangesinEarlyStagesofChronicKidneyDiseases
: F Diseases Volume 16 Issue 2 Version 1.0 Year 2016 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN: 2249-4618 & Print ISSN: 0975-5888
More informationOPEN. Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura
www.nature.com/scientificreports Received: 26 September 2017 Accepted: 19 March 2018 Published: xx xx xxxx OPEN Long-term effects of low calcium dialysates on the serum calcium levels during maintenance
More informationModified percutaneous ethanol injection of parathyroid adenoma in primary hyperparathyroidism
Q J Med 2008; 101:657 662 doi:10.1093/qjmed/hcn062 Advance Access published on 22 May 2008 Modified percutaneous ethanol injection of parathyroid adenoma in primary hyperparathyroidism C. CAPPELLI, G.
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationSevelamer Decreases Serum Uric Acid Concentration through Adsorption of Uric Acid in Maintenance Hemodialysis Patients
ORIGINAL ARTICLE Sevelamer Decreases Serum Uric Acid Concentration through Adsorption of Uric Acid in Maintenance Hemodialysis Patients Iwao Ohno 1, Yuichiro Yamaguchi 1, Hajime Saikawa 1, Daijiro Uetake
More informationHyperphosphatemia Modestly Retards Parathyroid Hormone Suppression during Calcitriol-Induced Hypercalcemia in Normal and Azotemic Rats
Original Paper Nephron 2002;92:883 888 DOI: 10.1159/000065454 Accepted: May 22, 2002 Hyperphosphatemia Modestly Retards Parathyroid Hormone Suppression during Calcitriol-Induced Hypercalcemia in Normal
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationPARSABIV (etelcalcetide)
PARSABIV (etelcalcetide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 23, 2007 Alicja E. Grzegorzewska, Monika Mĺot Michalska Serum Level of Intact Parathyroid Hormone and Other Markers of Bone Metabolism
More informationChapter 5: Evaluation and treatment of kidney transplant bone disease Kidney International (2009) 76 (Suppl 113), S100 S110; doi: /ki.2009.
http://www.kidney-international.org & 2009 KDIGO Chapter 5: Evaluation and treatment of kidney transplant bone disease ; doi:10.1038/ki.2009.193 Grade for strength of recommendation a Strength Wording
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationA clinical assessment of the relationship between bone scintigraphy and serum biochemical markers in hemodialysis patients
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 18, No. 6, 513 518, 2004 A clinical assessment of the relationship between bone scintigraphy and serum biochemical markers in hemodialysis patients Seiji
More informationPrimary hyperparathyroidism (HPT) has an incidence of
Dual-Phase Tc-Sestamibi Imaging: Its Utility in Parathyroid Hyperplasia and Use of Immediate/ Delayed Image Ratios to Improve Diagnosis of Hyperparathyroidism Leonie Gordon, MD; William Burkhalter, MD;
More informationParicalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients
Pediatr Nephrol (2006) 21:1434 1439 DOI 10.1007/s00467-006-0204-5 ORIGINAL ARTICLE Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients Wacharee Seeherunvong
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationProliferation in hyperplastic human and normal rat parathyroid glands: Role of phosphate, calcitriol, and gender
Kidney International, Vol. 64 (2003), pp. 2311 2317 Proliferation in hyperplastic human and normal rat parathyroid glands: Role of phosphate, calcitriol, and gender YOLANDA ALMADEN, ARNOLD J. FELSENFELD,
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationWhy has the gross mortality of dialysis patients increased in Japan?
Kidney International, Vol. 57, Suppl. 74 (2000), pp. S-60 S-65 Why has the gross mortality of dialysis patients increased in Japan? MORTALITY TAKASHI AKIBA, SHIGERU NAKAI, TORU SHINZATO, CHIKAO YAMAZAKI,
More informationPREDICTIVE FACTORS FOR PERSISTENT HYPERPARATHYROIDISM AFTER KIDNEY TRANSPLANTATION
Arch Iranian Med 2005; 8 (4): 295 299 Original Article PREDICTIVE FACTORS FOR PERSISTENT HYPERPARATHYROIDISM AFTER KIDNEY TRANSPLANTATION Gholamhossein Rangbar-Omrani MD *, Mohammad-Hossein Dabbaghmanesh
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More informationRenal Bone Disease: 25-year Experience From a Single Center
Original Article Renal Bone Disease: 25-year Experience From a Single Center Kwok-Hong Chu, 1 Au Cheuk, 1 William Lee, 1 Ka-Fai Yim, 1 Hon-Lok Tang, 1 Ka-Shun Fung, 1 Kam-Cheong Lee, 2 Kwok-Lung Tong,
More informationCLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)
CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) Dr Simon Steddon, Consultant Nephrologist, Guy s and St Thomas NHS Foundation Trust, London Dr Edward Sharples,
More information